Daewoong Pharmaceutical and Hanall Biopharma have announced their investment in Alloplex Biotherapeutics by purchasing to support a potential long-term collaboration for developing new cancer cell therapies. Daewoong Pharmaceutical and Hanall Biopharma aim to collaborate with Alloplex to develop global networks and communication with experts in this domain.

This investment will allow Alloplex to advance its first-generation SUPLEXA therapeutic cell program into the clinic by the first half of 2022. SUPLEXA Therapeutic Cells are a differentiated and non-engineered autologous therapy made from activated and reprogrammed peripheral blood mononuclear cells (PBMC) - derived from patient whole blood. SUPLEXA cells are generated in rapidly and in abundance through a robust ex vivo manufacturing procedure during which they acquire the capacity to kill all tumor cells tested without affecting normal cells. SUPLEXA cells are comprised of a heterogenous mixture of cells of both innate and adaptive phenotypes known for their anti-tumor activity, including NK, NKT, CD8+ CTL and gd T cells.

As such SUPLEXA cells employ a multi-modal anti-tumor strategy comprised entirely of normal activated immune cells with a capacity to kill all tumor cells tested. It is postulated that by using the patient's own cells rather than external substances that this therapy may have a very benign safety profile while maximizing anti-cancer effects.